Table 2.
Donor Source, HLA match, Graft-versus-Host disease (GVH) prophylaxis and Granulocyte Transfusion.
| Patient | Donor Source | HLA Match (of 6) | Total Nuc. Cell Dose (x107/kg) | GvH Prophylaxis | Granulocyte Infusions | Conditioning Regimen |
|---|---|---|---|---|---|---|
| 1 | Sibling Bone Marrow | 6 | 79.4 | Csa/Mtx | No | Busulfan/Cytoxan |
| 2 | Sibling Bone Marrow | 6 | 16.6 | Csa/Mtx | No | Busulfan/Cytoxan |
| 3a* | Sibling Bone Marrow | 6 | NA | Csa/TCD | No | Fludarabine/Cytoxan + eATG |
| 3b | Sibling Bone Marrow | 6 | 40 | Csa/Mtx | No | Fludarabine/Busulfan/Cytoxan + rATG |
| 4 | Sibling Bone Marrow | 6 | 34.8 | Csa/Mtx | No | Busulfan/Cytoxan |
| 5a* | Unrelated Cord Blood | 5 | 4.15 | Csa/Steroid | Yes | Busulfan/Cytoxan + eATG |
| 5b | Unrelated Cord Blood | 5 | 4.14 | Csa/Steroid | Yes | TBI(200cGy)/Fludarabine/Cytoxan |
| 6 | Sibling Bone Marrow | 6 | 55 | Csa/Mtx | No | Busulfan/Cytoxan + eATG |
| 7a* | Unrelated Cord Blood | 5 | 8.5 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
| 7b | Unrelated Cord Blood | 4 | 6.87 | Csa/MMF | Yes | Campath/Fludarabine/Cytoxan |
| 8 | Unrelated Cord Blood | 5 | 3.47 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
| 9 | Unrelated Cord Blood | 5 | 4.8 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
| 10 | Sibling Cord Blood | 6 | 3.2 | Csa/Steroid | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
| 11 | Unrelated Cord Blood | 5 | 12.6 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
| 12 | Unrelated Cord Blood | 6 | 11.2 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
ATG: Anti-thymocyte globulin, eATG: equine ATG, rATG: rabbit ATG. Csa: Cyclosporine, Mtx: Methotrexate, MMF: Mycophenolate Mofetil, TCD: T-cell depleted